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Background: Corticosteroids are illegally used in several countries as growth promoters in veal calves and beef
cattle, either alone or in association with sex steroids and β-agonists, especially at low dosages and primarily
through oral administration, in order to enhance carcasses and meat quality traits. The aim of the present study is
to evaluate the reliability of the histological evaluation of the thymus, as well as the serum cortisol determination,
in identifying beef cattle, treated with two different dexamethasone-based growth-promoting protocols and the
application of different withdrawal times before slaughter.
Results: Our findings demonstrate that low dosages of dexamethasone (DXM), administered alone or in association
with clenbuterol as growth promoter in beef cattle, induce morphologic changes in the thymus, resulting in
increase fat infiltration with concurrent cortical atrophy and reduction of the cortex/medulla ratio (C/M). In fact, the
C/M value was significantly lower in treated animals than in control ones, with both the protocols applied. The cut
off value of 0.93 for the cortex/medulla ratio resulted to be highly effective to distinguish control and treated
animals. The animals treated with DXM showed inhibition of cortisol secretion during the treatment period, as well
as at the slaughterhouse, 3 days after treatment suspension. The animals treated with lower doses of DXM in
association with clenbuterol, showed inhibition of cortisol secretion during the treatment period, but serum cortisol
concentration was restored to physiological levels at slaughterhouse, 8 days after treatment suspension.
Conclusions: The histological evaluation of thymus morphology, and particularly of the C/M may represent a
valuable and reproducible method applicable to large-scale screening programs, due to the easy sampling
procedures at slaughterhouse, as well as time and cost-saving of the analysis. Serum cortisol determination could
be considered as an useful in vivo biomarker of dexamethasone illegal treatment in beef cattle during the fattening
period, whilst it does not appear to be a good biomarker at the slaughterhouse, since the protocol of DXM
administration, as well as the withdrawal period could affect the reliability of the method.
Keywords: Beef cattle, Indirect biomarker, Cortisol, Cortex/medulla ratio, Dexamethasone, Thymus* Correspondence: mvascellari@izsvenezie.it
Istituto Zooprofilattico Sperimentale delle Venezie, viale dell’Università 10,
35020, Legnaro, PD, Italy
© 2012 Vascellari et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Vascellari et al. BMC Veterinary Research 2012, 8:129 Page 2 of 12
http://www.biomedcentral.com/1746-6148/8/129Background
Corticosteroids are illegally used in several countries as
growth promoters in veal calves and beef cattle, either
alone or in combination with anabolic agents, especially
at low dosages and primarily through oral administration,
in order to enhance carcasses and meat quality traits
[1,2]. These drugs are usually used in association with
sex steroids and β-agonists to obtain a higher proportion
of lean meat [3]. The strong pharmacological activity of
synthetic corticosteroids renders the residues of these
molecules potentially dangerous for meat consumers. As
a consequence, corticosteroids administration as growth-
promoters is banned in the EU (Council Directive 96/23/
EC) [4]. For therapeutic indications only, the use of some
glucocorticosteroids is allowed and therefore maximum
residue limits (MRLs) have been established for bovine
edible tissues (0.75 μg/kg in kidney and muscle, and
2 μg/kg in liver) and milk (0.3 μg/kg) (Commission Regu-
lation (EC) N. 508/1999) [5].
Unfortunately, the targeted gas chromatography/mass
spectrometry (GC/MS) and liquid chromatography tan-
dem mass spectrometry (LC/MS/MS) methods used may
give unsatisfactory results, due to the growing use of very
low individual doses, achieved by combining several pro-
ducts to produce synergistic effects (‘cocktails’), as well as
the use of products known to be difficult to analyze be-
cause of their rapid metabolism [6]. Furthermore, the use
of low-dosage drug cocktails causes only minimal tissue
changes thus hampering the detection of suspected
alterations in target organs [6,7]. For these reasons,
screening methods based on different approaches, in-
cluding the measurement of indirect biomarkers and the
use of histological and physiological indicators, are
strongly required. Innovative methods that can be useful
in identifying animals treated with anabolic agents in-
clude the so-called omics techniques (transcriptomic,
proteomic and metabolomic), based on the simultaneous
detection of biomarkers predictive of administration of
specific substances [8-12]. Since 2009, histological exam-
ination of the thymus has been introduced by the Minis-
try of Health in Italy as a screening test to control the
illegal use of corticosteroids in veal calves and beef cattle
(Piano Nazionale Residui 2009 – Ministero della Salute)
[13]. The role of histological examination of the thymus
as a biomarker of illegal corticosteroid treatment has
been established [7,14,15], but it is nevertheless difficult
to discriminate between anabolic and therapeutic treat-
ment. In addition, in adult cattle, it is difficult to distin-
guish between the physiological rate of involution and
the atrophy induced by treatment.
If the effect of non-therapeutic doses of dexametha-
sone in beef cattle on growth performance and
carcass traits is well known [1,2,6], its effect on hor-
monal, hematological and biochemical parameters isstill matter of investigation. The potential modification
of hematological and endocrine parameters induced
by treatment could be used to identify illegally treated
animals at the farm and slaughterhouse levels, and
the association of additional indirect indicators may
be helpful in enhancing the sensitivity and specificity
of the method.
The aim of the present study was to evaluate the reli-
ability of the histological evaluation of the thymus, as
well as the serum cortisol determination, in identifying
beef cattle treated with two different dexamethasone-
based growth-promoting protocols and the application
of different withdrawal times before slaughter.
Methods
Animals and treatments
A total of 42 Charolaise beef cattle, aged between 19 and
21 months, were bought by local farms and underwent
clinical controls by a veterinarian. All the animals were
vaccinated against IBR, Para Influenza (PI3), BRSV and
BVDV (CATTLEMASTERW 4; Pfizer Animal Health,
New York, USA) and treated against parasites with iver-
mectina (IvomecW, Merial, Italy). After a 19 days of ac-
climation period the animals were randomly divided in 3
groups: group A (n = 18) that served as control group; in
group B (n = 16) 0.75 mg/day dexamethasone-21-so-
dium-phosphate (DesashockW; Fort Dodge Veterinaria,
Olot, Spain) were orally administered for 42 days (days
1–42); group C (n = 8) was given 0.66 mg/day dexa-
methasone-21-sodium-phosphate (DesashockW; Fort
Dodge Veterinaria, Olot, Spain) for 21 days (days 8–28)
and clenbuterol hydrochloride (Sigma Aldrich, St. Louis,
MO) at doses of 2 mg/day (days 1–7), 4 mg/day (days
8–14) and 6 mg/day (days 15-28) orally. Animals of
group A and B were slaughtered after a three-day with-
drawal period, while the animals of group C were
slaughtered after a eight-day withdrawal period. All the
animals were kept in separate boxes, and fed with a diet
consisting of hay and a commercial compound feed
based on hybrid corn, soybean meal, bran and barley;
water was supplied ad libitum. Clinical check-ups were
carried out daily by a veterinarian. At the end of the
sampling procedure carcasses of treated animals were
destroyed according to the law in force.
The experiment was authorised by the Italian Ministry
of Health and the Ethics Committee of the University of
Bologna and carried out according to European Eco-
nomic Community Council Directive 86/609 [16], which
is recognized and adopted by the Italian Government
(D.L. 27/01/1992 no. 116) [17].
Chemical analysis
Drug administration during the whole treatment protocol
was monitored collecting urine in the morning, once a
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urine and liver at slaughterhouse were also determined.
DXM in urine and liver was calculated by means of in-
ternally validated analytical methods. Briefly, urine sam-
ples, after deconjugation with helix pomatia, were
subjected to a purification step by solid phase extraction
(SPE) on a C18 column (500 mg/6 mL) followed by a fil-
tration through a NH2 SPE cartridge (100 mg, 1 mL),
while liver samples were extracted with acetonitrile and
purified by a single C18 (500 mg/6 mL) SPE step. Purified
extracts were finally analyzed by an HPLC (Alliance 2695,
Milford, MA, USA, Waters), coupled to a triple-
quadrupole mass spectrometer (Quattro Ultima, Micro-
mass, Waters, Milford, MA, USA) operating in negative
electrospray ionization. The chromatographic separation
was achieved by a Synergi-polar C18 column (150 x
2.00 mm, 4 μm, Phenomenex, Torrance, CA, USA),
adopting 0.05% (v/v) formic acid in water (eluent A) and
0.05% (v/v) formic acid in acetonitrile (eluent B) as mobile
phases. Gradient elution was performed combining the
mobile phases (A:B) as follows: 85:15 from 0 to 1 min,
70:30 at 5 min, 70:30 at 6 min, 65:35 at 16 min, 20:80 from
17 to 20 min, and then 85:15 from 21 to 26 min to re-
equilibrate the system. The flow-rate was set to
0.250 mL min-1 and the injection volume was 10 μL.
Mass spectrometric analyses were performed using the
following settings: nebulisation and desolvation were
achieved using nitrogen gas at flow-rates of 50 and
900 L h-1, respectively. Source and desolvation tempera-
tures were 125°C and 325°C. The potential applied on
the capillary was 2.7 kV and the potential applied on
the cone was optimized for each molecule in the
range between 40–50 V. MS/MS experiments were
performed using argon as the collision gas at a pres-
sure of 3.5*10-3 mbar and two selective transitions
(437 > 361 m/z and at 437 > 307 m/z, collision energy
equal to 18 and 31 eV respectively) were chosen for
unequivocal identification of DXM residues. DXM was
identified on the basis of the retention time and ion
ratios of the selected transitions. Quantification was
performed adopting dexamethasone-D4 (deuterated
DXM, 441 > 363 m/z, 19 eV) as internal standard.
The methods were developed and validated according
to the guidelines laid down by 2002/657/EC Commission
Decision [18]. Specificity was assessed on twenty differ-
ent blank samples (i.e. bovine urine and liver) that were
extracted and analyzed to verify the absence of interfer-
ences due to the matrix or endogenous components.
The linearity of the LC-MS/MS response was verified
using four calibration levels of standard solutions in
matrix to take into account the matrix effect on
ionization. Recovery and repeatability were assayed in
three separate working sessions, by spiking blank sam-
ples at three different concentrations with six replicatesfor each level. Quantification was achieved by internal
standard method using independent calibration curves
in each session. Decision limits were calculated accord-
ing to the calibration curve procedure established by
ISO 11843.
Histopathology
Portions of the thoracic thymus of each animal were col-
lected soon after slaughter and fixed in 10% neutral buf-
fered formalin and paraffin embedded according to
routine procedures. Representative sections of each sam-
ple were stained with hematoxylin and eosin for histo-
logical examination. Histopathological examinations
were blindly performed. The morphology of the thymus
parenchyma was evaluated for adipose tissue infiltration,
with concurrent cortical atrophy, and a score from 1 to
3 (mild, moderate, severe) was attributed.
Furthermore, the thymus sections were examined at
low magnification (4x) using a digital microimaging de-
vice (Leica DMD108 Digital microimaging device for
clinical diagnostics labs, Wetzlar, Germany) to evaluate
cortex and medulla thickness, according to the method
described by Bozzetta et al. [19]. For each slide, 5 func-
tional lobules, composed of an outer cortex and inner
medulla and surrounded by connective and adipose tis-
sues, were randomly selected and the extension of the
cortex and medulla were measured against a graduated
line, starting and ending at the interlobular connective
or adipose tissue; a second parallel line was drawn to
measure medulla thickness (Figure 1). The cortex thick-
ness was obtained by subtracting the second value from
the first one and the cortex/medulla ratio (C/M) was
calculated.
Serum cortisol determination
Individual blood samples were taken from the jugular
vein of the animals of the three groups, in the morning
of the first day of treatment, before drugs administration
(T0), on day 28 of treatment (T28) and at slaughter-
house, before stunning. Blood was collected in 10 mL
tubes without anticoagulant (Becton Dickinson, Meylan
Cedex, France) in the morning, before diet administra-
tion and at slaughterhouse immediately after stunning.
Serum samples were obtained after clot formation at
room temperature and centrifugation at 2500 g at 20°C
for 10 minutes. Serum cortisol concentration was deter-
mined using a commercial kit (Catalog Number:
LKCO1, Siemens Medical Solutions Diagnostics, Flan-
ders, NJ), performed with the automated analyzer
Immulite OneW (Siemens Medical Solutions Diagnostics,
Flanders, NJ) by chemiluminescent immunometric
assays. The method underwent internal validation. Ana-
lytical variability was measured with the use of two in-
ternal serum pools with low (7,4 nmol/L) and high
Figure 1 Measurement of the thymus cortex and medulla. Extension of the cortex was measured against a graduated line, starting and
ending at the interlobular connective or adipose tissue; a second parallel line was drawn to measure medulla thickness (HE 5X).
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assay coefficients of variation were 12.9% and 14.0% for
low serum pool, 5.1% and 7.4% for high serum pool. The
analytical sensitivity of the assay was 5.5 nmol/L. The
cortisol serum concentration values under the analytical
sensitivity were considered equal to 5.5 nmol/L.
Statistical analysis
The association between thymus score and group was
assessed by Fisher’s exact test.
The distributions of cortex thickness, medulla thick-
ness and C/M among groups were evaluated using a lin-
ear mixed model, after having transformed the data
using square root function for the first two parameters
and logarithmic function for the last one, in order to fit
the Gaussian distribution of data. The fixed effect was
the treatment group while the random effect was the
animal nested within group; lobules, collected for each
animal, represented the residual. The analysis was per-
formed considering the three groups (A, B and C) and B
and C together (treated group). In the former, all pair-
wise comparisons were carried out using Bonferroni ad-
justment. Furthermore, the linear mixed model,
stratified by treatment group, was used to compare the
distribution of C/M among thymus scores (fixed effect).
The analysis of residuals was adopted for checking the
models.With regard to animals with thymus score 2, a ROC
analysis was carried out to identify a cut-off of the C/M
able to discriminate lobules belonging to treated and un-
treated animals; for this analysis the five lobules, for each
thymus sample, were considered as independent statis-
tical units and, given that lower values of C/M were sup-
posed to belong to treated animals, the ratio was
multiplied by −1. To discriminate treated and untreated
animals, the number of lobules for each thymus sample
with a C/M under the cut-off value was calculated, and
positive and negative predictive values (PPV and NPV,
respectively) were provided considering the treatment
group as gold standard.
The serum cortisol concentrations of the three treat-
ment groups, stratified by sampling time, were evaluated
using the Kruskal-Wallis test. The Wilcoxon rank-sum
test was used for the pairwise comparisons and the
Bonferroni-corrected alpha was used to evaluate the
results. In addition, robust test for equality of variance,
with the Brown and Forsythe adjustment, compared the
variability of the distributions across the groups. For
each treatment group, the serum cortisol concentration
among different sampling times was evaluated by the
Wilcoxon matched-pairs signed-ranks test.
All data analyses were performed using SAS 9.1 Ver-
sion (SAS Institutem Inc., Cary, NC, USA).
The P value of 0.05 was considered as the level of stat-
istical significance.
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All the farmed animals concluded the experimental trial
without insurgence of clinical complications and there-
fore no medical treatments were required.
Chemical analysis
The analytical methods fulfilled the European require-
ments and were considered adequate for the analytical
purposes of this study; in particular, recovery was better
than 95%, precision was lower than 6.5% and calculated
decision limits (CCα) were 0.251 μg/L in urines, and
0.247 μg/Kg in liver.
Analysis of urine samples collected during the treat-
ment period demonstrated that the oral administration
protocol resulted in uptake of DXM (average DXM ran-
ged between 0.8 and 2.2 μg/L) in both groups B and C.
In group B (3-days withdrawal period) DXM urinary
concentration at the slaughterhouse ranged from 0 to
0.48 μg/L. Only 7 out of 16 animals (43.8%) showed a
DXM residue higher than the CCα of the method
(0.251 μg/L). DXM residues in liver samples (>CCα)
were detected in all the animals of group B, with con-
centrations ranging between 0.70 and 7.40 μg/Kg.
In group C (8-day withdrawal period) all the urine
samples collected at the slaughterhouse had DXM con-
centration largely below the CCα, with putative extrapo-
lated values ranging between 0 and 0.03 μg/L; by
contrast in liver samples DXM residues (>CCα) were
detected in 2 out of 8 animals (25%).
As expected, no DXM residues were detected in urine
and liver samples collected during the treatment period
as well as at the slaughterhouse, from animals of the
control group A. Table 1 reports the mean values ±
standard deviations calculated taking into account only
samples with residual concentrations higher than CCα.
Histopathology
On histological examination, score 1 was attributed to
samples with slight physiological thymus atrophy, due to
mild infiltration of adipose tissue at the periphery of the
lobules (Figure 2). Score 2 was referred to samples with
moderate fat interstitial infiltration, with thinning and
initial replacement of the cortex (Figure 3). Score 3 was
attributed to samples with severe adipose tissue infiltra-
tion of the parenchyma, with pronounced cortex atrophy
(Figure 4). In some samples the lobular structures wereTable 1 Chemical analysis of DXM residues (>CCα) from liver
Sample Number of posit
Group A
Liver [μg/kg] 0/18
Urine [μg/L] 0/18not recognizable, and they were almost completely
replaced by fat tissue leaving only scattered lymphocytes
aggregates. On blinded analysis, the scores 1 (n = 12) and
2 (n = 6), indicating the presence of mild and moderate
amounts of infiltrating fat, respectively, were attributed
to the group A (controls); in group B 4 samples were
scored 2 and 12 samples were scored 3 (severe infiltra-
tion). In group C 6 samples were scored 2 and 2 were
scored 3 (Table 2).
The thymus scores distributions resulted to be signifi-
cantly different among the three groups (P < 0.001).
When groups B and C (treated) were taken together the
thymus scores were significantly associated with the ster-
oidal treatment (P < 0.001).
Descriptive statistics for cortex thickness, medulla
thickness and C/M, stratified by treatment group, are
provided in Table 3. The cortex thickness resulted to be
significantly different among groups (P < 0.001); on the
contrary, the medulla thickness resulted to be not sig-
nificantly different among groups (P 0.552). Considering
the C/M, group A showed values ranging from 0.56 to
4.43 with an average of 1.62. In group B, the C/M was
not calculated in 5 samples due to the severe fat infiltra-
tion and the lack of functional lobules; among the
remaining samples, C/M values ranged from 0.14 to
1.69, with an average of 0.53. In group C the C/M was
calculated for 7 out of 8 animals, and the values ranged
from 0.25 to 1.51, with an average value of 0.69. Table 4
shows the results of the pairwise comparisons performed
by linear mixed models. The distribution of C/M values
among the three groups resulted to be significantly dif-
ferent (P < 0.001); particularly, the C/M values were sig-
nificantly different between group A and B (P < 0.001),
as well as between group A and C (P < 0.001), while no
statistical differences were observed between groups B
and C (P= 0.083) (Figure 5). Taking together groups B
and C (treated) the C/M values resulted to be signifi-
cantly different from those of the group A (P < 0.001).
Comparing the C/M values of samples from the same
treatment group, but with different thymus scores, no
significant differences were observed (group A:
P= 0.414; group B+C: P =0.723) (Figure 6).
Taking in consideration the animals with thymus score
2 (n = 15; 6 in group A, 4 in group B and 5 in group C),
the distribution of the C/M values between the groups A
and B, as well as A and C resulted to be significantlyand urine samples collected at the slaughterhouse
ive animals (mean value ± Standard deviation)
Group B Group C
16/16 (2.35 ± 1.81) 2/8 (0.28 ± 0.03)
7/16 (0.33 ± 0.09) 0/8
Figure 2 Thymus morphology of a control animal (group A). The score 1 was attributed to samples with slight physiological thymus atrophy,
due to mild infiltration of adipose tissue at the periphery of the lobules (HE 0.3X).
Figure 3 Thymus morphology of a treated animal (group C). The score 2 was referred to samples with moderate fat interstitial infiltration,
with thinning and initial replacement of the cortex (HE 0.3X).
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Figure 4 Thymus morphology of a treated animal (group B). the score 3 was attributed to samples with severe adipose tissue infiltration of
the parenchyma, with pronounced cortex atrophy (HE 0.3X).
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observed between groups B and C (P= 0.200). Consider-
ing together the groups B and C (treated), the distribu-
tion of the C/M values were significantly different from
the control group (P < 0.001). The best cut-off value of
the C/M to discriminate treated and untreated samples
resulted to be 0.93 (Area Under the Curve AUC 0.94;
95% CI 0.89-0.98) (Figure 7).
Considering five lobules for each thymus sample, ani-
mals with at least two lobules with C/M< 0.93 should be
considered as treated, providing a PPV and NPV bothTable 2 Thymus scores distribution in different groups,
based on the rate of adipose tissue infiltration, with
concurrent thymus cortical atrophy
Group Thymus Score N. of animals %
A 1 12 67
2 6 33
3 0 0
B 1 0 0
2 4 25
3 12 75
C 1 0 0
2 6 75
3 2 25equal to 100% (PPV 95%CI: 69.1%-100.0%; NPV 95%CI:
54.1%-100.0%).
Serum cortisol concentration
Baseline T0 values of serum cortisol showed high vari-
ability in all the three groups, ranging from 5.5 nmol/l
to 159.0 nmol/l , but no significant differences were
found among the groups (P= 0.061) (Table 5).
At T28, 22 of 24 animals in groups B and C showed
cortisol concentration under the analytical sensitivity
and were considered equal to 5.5 nmol/L; the distribu-
tion of the parameter in group A had a mean and a me-
dian values of 23.8 nmol/L and 18.3 nmol/L,
respectively, which resulted to significantly differ from
the treated groups (P < 0.001).
At the slaughterhouse, no statistical differences were
observed between the distributions of cortisol concen-
tration of group A and group C (P= 0.317); but, a signifi-
cant difference was found between group A and B
(P < 0.001). For both comparisons, a significantly higher
variability in group A than group C (P= 0.006) and
group B (P < 0.001) was found. Different distribution
(P< 0.001) of cortisol concentration but similar spread
(P= 0.239) were highlighted between group B and C.
The analysis carried out comparing the three different
sampling time in the control group (A) showed a signifi-
cant decrease of the serum cortisol concentration at T28
compared to T0 (P 0.031), followed by a significant
Table 3 Descriptive statistics for cortex thickness (μm), medulla thickness (μm) and C/M of thymus samples, by
treatment group
Parameter Group N. of lobules Mean Median SD Min Max
Cortex thickness A 90 795.4 763.5 254.4 298.0 1573.0
B 55 230.7 205.0 110.7 76.0 650.0
C 35 359.1 351.0 149.2 137.0 894.0
Medulla thickness A 90 539.8 548.5 173.0 206.0 1044.0
B 55 506.4 484.0 233.8 161.0 1120.0
C 35 569.4 505.0 239.7 244.0 1573.0
C/M A 90 1.62 1.47 0.71 0.56 4.43
B 55 0.53 0.42 0.32 0.14 1.69
C 35 0.69 0.64 0.31 0.25 1.51
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were observed between T0 and slaughterhouse sampling
(P 0.349).
Group B presented similar distributions of serum cor-
tisol values at T28 and slaughterhouse (P 0.099), which
were both significantly lower than at T0 (T28 vs T0: P
0.001; slaughterhouse vs T0: P 0.018).
With regard to group C, all pairwise comparisons
showed that p-values were lower than 0.05 (T0 vs T28: P
0.019; T0 vs slaughterhouse: P 0.012; T28 vs slaughter-
house: P 0.012), with a significant decrease of the serum
cortisol concentration during the treatment (T0 vs T28),
followed by a significant increase at the slaughterhouse
(T28 vs slaughterhouse and T0 vs slaughterhouse).
Discussion
The assurance of safe and good quality food is a funda-
mental request of the consumers. Dexamethasone and
other corticosteroids are frequently illegally used as
growth-promoters in livestock production [6], often
administered at low dosage alone or combined with β-
agonists and/or anabolic steroids.
In our study, the results of the chemical analysis in
urine and liver samples obtained at the slaughterhouse,Table 4 Results of linear mixed models applied to cortex thic
variables
Dependent variable Parameter
Cortex thickness square root A vs B
A vs C
B vs C
Medulla thickness square root A vs B
A vs C
B vs C
C/M log A vs B
A vs C
B vs Cconfirmed that when DXM is administered at low dos-
age, its rapid metabolism and excretion makes the resi-
dues determination difficult, as the drug is readily
depleted after the suspension of the treatment [20,21].
In fact, while in group B DXM residues were still detect-
able and identifiable in all liver samples, in animals of
group C, which were treated with lower dosage of DXM
and had a 8-day withdrawal period, DXM residues
(>CCα) were not detectable in liver of 6 out of 8 ani-
mals; moreover, DXM residues detected in 2 liver sam-
ples were lower than the MRL= 2 μg/Kg in liver
(Commission Regulation (EU) No 37/2010) [5]. Further-
more, the urine samples collected at the slaughterhouse,
had DXM concentrations largely below the CCα in 9
animals of group B, as well as in all the animals of group
C. These data are in accordance with the findings of a
previously published paper [15] evaluating DXM urine
excretion in beef cattle treated with low-dose of DXM
during the drug administration period, as well as 6 days
after the end of the treatment. DXM residues were
detected in all samples collected during the treatment,
although at low concentration levels, and were not de-
tectable anymore 6 days after treatment suspension [15].
Moreover, a recent study [22] evaluated drug residuekness, medulla thickness and C/M ratio as dependent










Figure 5 The distribution of C/M values among the three
groups. The C/M values resulted significantly different between
group A and B (P< 0.001), as well as between group A and C
(P< 0.001), while no statistical differences were observed between
groups B and C (P= 0.083).
Figure 7 ROC curve for C/M ratio with 95% confidence interval.
Taking in consideration the animals with thymus score 2, the best
cut-off value of the C/M to discriminate treated and untreated
samples resulted to be 0.93 (AUC 0.94; 95% CI 0.89-0.98).
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hair following a single administration of 0.15 mg/kg b.w.
dexamethasone acetate and 0.12 mg/kg b.w. dexametha-
sone sodium phosphate, by different analytical methods
based on GC-MS or LC-MS/MS; the results confirmedFigure 6 Comparison of the C/M values of samples from the
same treatment group, but with different thymus scores. No
significant differences were observed among control and treated
animals with different thymus scores (group A: P= 0.414; group
B +C: P =0.723).the high and rapid urinary excretion rate of DXM, with
a maximal concentration measured one day after admin-
istration and 98% elimination within 3 days [22].
Thus, novel screening tools are needed to accurately
reveal the illegal administration of corticosteroids by the
meat producing industry.
Our findings demonstrate that low dosages of DXM,
administered alone or in association with clenbuterol as
growth promoter in beef cattle, according to the proto-
cols often illegally adopted in farm practice [7], induce
morphologic changes in the thymus, resulting in in-
crease fat infiltration with concurrent cortical atrophy.Table 5 Descriptive statistics for serum cortisol
concentration (nmol/L) by treatment groups at different
sampling times
Sampling time Group Mean Median St. dev. Min Max
T0 A 48.2 43.3 34.2 5.7 108.0
B 30.1 15.8 37.9 5.5 159.0
C 24.3 11.8 26.0 5.5 76.1
T28 A 23.8 18.3 18.9 5.5 73.5
B 5.9 5.5 1.5 5.5 11.6
C 7.4 5.5 5.3 5.5 20.6
Slaughterhouse A* 65.9 57.0 47.3 7.0 140.0
B*} 9.1 5.5 7.8 5.5 35.4
C** 82.3 86.8 25.5 34.8 116.0
* 3 days withdrawal period.
**8 days withdrawal period.
}one observation not considered because outlier.
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corticosteroid administration in beef cattle [14,15], as
well as in veal calf [7,23] has been previously high-
lighted. However, the reliability of this method could be
affected by several factors, such as infectious diseases,
intoxication and stress [24]. In addition, in beef cattle it
is rather difficult to distinguish between physiological in-
volution and treatment-induced atrophy, and the thymus
score could be influenced by subjective inter-observer
variations. Our data indicate that the severity of the
histological alteration correlates with the administered
DXM dosages, as previously observed [25]. In fact,
among animals treated with lower doses of DXM in as-
sociation with a β-agonist (group C), thymus atrophy
was less evident than in group B, and many thymus sam-
ples were scored 2. Samples with thymus score 2 are not
discriminative, since they occur in both control and trea-
ted animals. The association of more objective para-
meters as indirect indicators may be helpful in
enhancing the sensitivity and specificity of the histo-
logical method. Administration of synthetic glucocorti-
coids, such as DXM, can cause acute thymus involution
and have been used as a model system [26,27]. Acute
thymic involution is characterized by reduction in thy-
mus size caused by acute loss of cortical thymocytes and
reduced output of native T cells to the periphery [28].
Differently, age-induced involution is characterized by a
gradual expansion of perivascular spaces and reduction
of thymic epithelial spaces capable of supporting thymo-
poiesis [24]. Other possible causes of thymus atrophy as
autoimmune phenomenon and immunodeficiency syn-
dromes have been shown to affect cellular density with
symmetrical reduction of thymic cortical and medullary
areas as well [29]. Our results indicate that the cortex/
medulla ratio is a simple and objective parameter, useful
for the detection of illegal treatment with low doses of
DXM, which could be applied independently from the
thymus score. In fact, the C/M value was strongly asso-
ciated with corticosteroids treatments, with both the
protocols applied. The cut off value of 0.93 for the C/M
resulted to be highly effective to distinguish control from
treated animals with thymus score 2. Furthermore, the
C/M value resulted to be not significantly associated
with the thymus score. This means that animals with dif-
ferent rates of fat tissue infiltration, due to age-related
involution or other factors, could be categorized in trea-
ted or untreated group on the basis of the C/M value. In
our model, considering 5 lobules randomly selected in
each thymus sample, animals with thymus score 2 and
at least 2 lobules having C/M< 0.93, should be consid-
ered as treated with corticosteroids, with a PPV and
NPV both equal to 100%. It should be emphasized that
the proposed cut-off value for the C/M has to be validated
by studies on a larger population, including different breedand ages of the animals. A similar approach were applied
in a recent study on veal calves, treated with low-doses of
DXM for 20 days [19]. Results of the study showed that
fat infiltration was not significantly associated with ster-
oidal treatment, while a significant reduction in the C/M
was observed in treated animals vs controls [19]. The find-
ings of both studies seem indicate that the C/M is strongly
related to steroidal treatment in both veal calves and beef
cattle, being more reliable than the evaluation of fat infil-
tration in thymus parenchyma. Assessment of the C/M,
once validated in a larger population sample, taking in
consideration the repeatability and the accordance be-
tween different diagnostic laboratories, could represent a
promising and standardizable method for screening pur-
poses, to evaluate the diffusion of corticosteroids illicit
treatments in beef production.
In our study, the serum cortisol concentration of con-
trol and treated animals was evaluated during the rear-
ing period, as well as at the slaughterhouse. Non treated
animals (group A), showed high variability in serum cor-
tisol concentration during the whole study period, with
higher median values at T0 and at the slaughterhouse,
imputable to physiological stress response to handling
and transport procedures [30,31]. The animals treated
with DXM showed inhibition of cortisol secretion during
the treatment period, as well as at the slaughterhouse,
3 days after treatment suspension. In fact, DXM acts
similarly as endogenous cortisol and inhibits hypothal-
amus and hypophysis activities exerting a negative effect
on ACTH secretion [32,33]. These data are in accord-
ance with the findings of a previous experimental study
in beef cattle [34], as well as with those of a field study
investigating the thymus morphology and serum cortisol
concentration in regularly slaughtered beef cattle [14]. In
the latter study the animals considered to be negative on
the basis of thymus morphology had a significantly
higher mean cortisol level than those suspected of cor-
ticosteroid treatment [14].
Animals of group C, which were treated with lower
doses of DXM in association with clenbuterol, showed
inhibition of cortisol secretion during the treatment
period, but serum cortisol concentration was restored to
physiological levels at slaughterhouse, 8 days after treat-
ment suspension, indicating that the withdrawal period
could affect the reliability of the method.
Conclusions
Our findings support the need for development of new
screening methods based on indirect biomarkers, to orien-
tate controls by confirmatory methods. In this regard, the
histological evaluation of thymus morphology, and particu-
larly of the C/M may represent a valuable and reproducible
method applicable to large-scale screening programs, due
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http://www.biomedcentral.com/1746-6148/8/129to the easy sampling procedures at slaughterhouse, as well
as time and cost-sparing of the analysis.
The serum cortisol determination could be considered
as an useful in vivo biomarker of DXM illegal treatment
in beef cattle during the fattening period, whilst it does
not appear to be a good biomarker at the slaughter-
house, since the protocol of DXM administration, as well
as the withdrawal period could affect the reliability of
the method.
Furthermore, the great variability of cortisol baseline
values detected in farmed animals at T0, suggests that
serum cortisol determination for surveillance policy pur-
pose should be performed on several animals (batch) to
account for the inter-individual variability.
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